Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia

Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia

US Patent 10933132 · Granted Mar 2, 2021

Estimated economic value: $464,158,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Reducing CD33 expression to selectively protect therapeutic cells2025
Anti-CD33 antibodies and uses thereof2024
Trispecific molecule combining specific tumor targeting and local immune checkpo2022
Administration of a bispecific construct binding to CD33 and CD3 for use in a me2021
Method and microtome for producing thin sections with a section profile recordin2019
Microtome having a piezoelectric linear actuator2017
Knife holder having a blade changing apparatus2016
Blade dispenser2015
Microtome having an auto-rocking mode2015
Method and device for producing thin sections of a sample by means of an image r2014
Method of cutting at least one thin section and tagging at least one specimen sl2013
Apparatus and method for identifying at least one specimen slide2013